CVS

CVS’s moat is its scaled, vertically integrated model across Pharmacy, PBM (Caremark), and insurance (Aetna), which supports cross-selling, member retention, and data-driven care navigation. Q1 2026 results suggest execution is improving in Health Care Benefits after a choppy period, and the March 5, 2026 Google Cloud partnership (Health100) could strengthen engagement and adherence, but monetization timing is uncertain. Industry-wide, managed care pricing discipline and utilization trends remain key swing factors for margins.

Financially, CVS is growing from a very large base: full-year 2025 revenue was $402.1B, and Q1 2026 revenue was $100.4B (+6.2% YoY) with adjusted EPS of $2.57 and GAAP EPS of $2.30. Management raised 2026 adjusted EPS guidance to $7.30–$7.50 and lifted cash flow from operations guidance to at least $9.5B, supporting de-levering and shareholder returns (annual dividend is $2.66/share, about a mid-3% yield based on recent quotes). Valuation looks optically distorted on trailing GAAP (high TTM P/E), while forward P/E screens closer to low-teens; investors should focus on normalized earnings power and medical cost trends.

Over the next 12 months, the thesis hinges on sustained improvement in Health Care Benefits margins, stabilization in utilization, and CVS proving it can grow earnings without relying on one-off items. Catalysts include continued guidance raises and evidence that the pharmacy/PBM stack is defending share amid pricing pressure. Key risks are adverse medical cost development, reimbursement pressure in retail pharmacy, and regulatory actions affecting PBM economics.

Recommendation: HOLD. The raise to 2026 guidance and strong cash generation argue for downside support, but the stock needs clearer, durable margin recovery (and cleaner GAAP comparability) to justify multiple expansion.